Novo Nordisk’s Once-Weekly Insulin Gains Superiority Finding As Lilly Advances
Executive Summary
The ONWARDS 1 and 6 results closely follow success in ONWARDS 2 in April, further helping strengthen insulin icodec’s potential market position, but Lilly is nipping at Novo’s heels.
You may also be interested in...
Pipeline Watch: 10 Approvals And 12 Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lilly Aims For Earlier Treatment With Novel Diabetes Drugs
Lilly outlined its tirzepatide-led pipeline of incretin agonists and highlighted its once-weekly basal insulin during a post-ADA event. The company hopes to grow the GLP-1 market overall rather than shift patients from Trulicity.
Novo Nordisk Goes ‘Full-Speed Ahead’ Towards Once-Weekly Basal Insulin
Novo Nordisk’s once-weekly injected basal insulin icodec could be a boon to the many people with type 2 diabetes who are reluctant to start on insulin therapy due to the need for daily injections, the Danish group’s head of development tells Scrip.